Healthcare Services

Gastrointestinal Cancer Market: Developments Driving Growth

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastrointestinal Cancer Market Over The 2026–2030 Period?

The gastrointestinal cancer market has experienced rapid growth in recent years. It is forecast to expand from $27.05 billion in 2025 to $30.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical growth can be linked to several factors, including the increasing occurrence of gastrointestinal cancers, the development of diagnostic imaging technologies, greater public awareness for prompt cancer detection, progress in oncology drug creation, and improved accessibility to cancer care facilities.

The gastrointestinal cancer market is projected to experience substantial expansion in the coming years. It is set to reach $47.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This anticipated growth during the forecast period is primarily driven by factors such as greater investments in personalized oncology, the increasing embrace of biomarker-based diagnostics, the broadening of immuno-oncology pipelines, the expanding application of minimally invasive diagnostics, and a rise in healthcare spending allocated to cancer treatment. Key trends anticipated during the same period encompass the growing acceptance of targeted GI cancer therapies, an uptick in the utilization of molecular diagnostics, an intensified focus on immunotherapy combinations, the broadening of early cancer screening initiatives, and the improved incorporation of precision medicine.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Gastrointestinal Cancer Market?

The increasing embrace of targeted therapies is projected to fuel the expansion of the gastrointestinal cancer market moving forward. These treatments function by precisely hindering cancer cell proliferation through interaction with specific molecular targets, thereby minimizing harm to normal, healthy cells. Targeted therapies are designed to intervene in particular molecular pathways or genetic mutations that drive disease, especially in cancer. Unlike conventional treatments such as chemotherapy, which attack both healthy and diseased cells indiscriminately, targeted therapies concentrate on the distinct characteristics of a patient’s condition. For gastrointestinal (GI) cancer, these therapies act on specific genes or proteins that regulate tumor growth, offering precise and effective treatment. This yields superior outcomes with fewer side effects compared to traditional chemotherapy. For instance, in July 2023, as reported by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, the number of gene therapies in Phase II stood at 247 at the end of quarter one (Q1) 2023, subsequently rising by 5% to reach 260 by the end of quarter two (Q2). Thus, the growing adoption of targeted therapies is indeed propelling the growth of the gastrointestinal cancer market.

Which Segment Types Are Examined In The Gastrointestinal Cancer Market Segment Study?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

Which Trends Are Shaping The Gastrointestinal Cancer Market?

Leading companies in the gastrointestinal cancer market are concentrating on developing advanced solutions, such as monoclonal antibody treatment, to enhance patient survival rates and mitigate treatment-related adverse effects. Monoclonal antibody treatment involves the use of laboratory-produced antibodies designed to precisely identify and attach to cancer cells, thereby assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, following approval from the European Commission. This therapy is intended as a first-line treatment for adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval positions VYLOY as the inaugural and sole therapy available in the European Union that targets CLDN18.2, a biomarker found in approximately 38% of these patients, supported by encouraging clinical trial data from the SPOTLIGHT and GLOW studies.

Which Players Are Part Of The Competitive Landscape Of The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Get The Full Gastrointestinal Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Region Leads The Gastrointestinal Cancer Market In Terms Of Market Share?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastrointestinal Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Colorectal Cancer Molecular Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Colorectal Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795